Descripción del proyecto
Impresión 3D de órganos para una medicina hepática regenerativa
Las enfermedades hepáticas causan al año dos millones de muertes en todo el mundo. Aunque el trasplante de hígado es el modo más eficaz de recuperar el funcionamiento normal en diversas enfermedades, por ejemplo la insuficiencia hepática aguda o las neoplasias hepáticas, actualmente no se pueden cubrir ni el 10 % de las necesidades mundiales de trasplantes. El proyecto financiado con fondos europeos ORGANTRANS se propone sustituir el trasplante de hígado para personas con insuficiencia hepática en fase final mediante el desarrollo de una plataforma de impresión 3D de tejidos hepáticos. El proyecto abarcará todo el ciclo de desarrollo, desde la fuente celular y la ingeniería de tejidos, a través de ensayos que permitan la adopción temprana de sus resultados en la práctica clínica. Cabe destacar que este estudio creará tecnologías innovadoras que pueden aplicarse a otros sistemas de órganos en medicina regenerativa.
Objetivo
End-stage liver failure is a major healthcare challenge. Liver diseases account for approximately 2 million deaths per year worldwide. Liver transplantation is the most effective way to re-establish a liver with normal functions for various diseases including acute liver failure or liver malignancies. Currently, less than 10% of global transplantation needs are met and the gap between patients on transplant waiting lists and available donor organs is steadily increasing.
ORGANTRANS proposes a disruptive alternative to donor organs for patients with chronic or end-stage liver diseases who have still to isolate autologous liver stem cells. Driven by a need of leading European transplant centers, ORGANTRANS will tackle current obstacles for liver regenerative medicine by combining advanced know-how in cell biology, biomaterials, bioengineering, automation, standardization and clinical translation.
ORGANTRANS will develop a liver tissue printing platform that will be shortly deployed under the “compassionate use exemption” by three leading European transplant centers belonging to the consortium or the External Advisory Board. ORGANTRANS will not only deliver an ATMP, but also platform technologies that can be scaled to other organ systems, as organoid technology is one of the largest parts of regenerative medicine. The project covers the entire value chain (from cell source, tissue engineering, bioprinting, post-processing to testing) allowing for early adoption of its results (product & process) in clinical practice. The platform will first be scaled to Europe and then to the rest of the world.
Ámbito científico
- natural sciencesbiological sciencescell biology
- medical and health sciencesmedical biotechnologytissue engineering
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicinehepatology
- medical and health sciencesclinical medicinetransplantation
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-2019-Single-Stage-RTD
Régimen de financiación
RIA - Research and Innovation actionCoordinador
2000 Neuchatel
Suiza